Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Anticipates Lucrative Atripla Launch In EU, Maintains Optimism About Letairis

This article was originally published in The Pink Sheet Daily

Executive Summary

Detailing its fourth-quarter and full-year 2007 financials, Gilead predicts nine-month rollout for Atripla in five major European nations.

You may also be interested in...



HIV Sales Fuel Gilead’s Robust First Quarter

Biotech firm boasts record sales, record revenues.

HIV Sales Fuel Gilead’s Robust First Quarter

Biotech firm boasts record sales, record revenues.

Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B

Company also awaits August PDUFA date for the same indication in the United States.

Related Content

Topics

UsernamePublicRestriction

Register

PS066770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel